Physician profile
Timothy Chen
NPI 1316917115
$1,198.97
in general payments reported to CMS, 2019-2025
15 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.99 · 2020: $159 · 2021: $37.42 · 2022: $438 · 2023: $132 · 2024: $172 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $421.74 | 2022 | |
| Stryker Corporation | $237.44 | 2020-2024 | Citrefix, 7 X 23mm Citrelock Implant |
| Averitas Pharma INC. | $151.20 | 2025 | Qutenza |
| Paratek Pharmaceuticals, INC. | $53.15 | 2024-2025 | Nuzyra |
| Lifenet Health | $52.05 | 2023-2024 | Theragenesis Wound Matrix |
| Smith+Nephew, INC. | $51.32 | 2023-2024 | Pico 7, Oasis, Grafix Pl |
| Wright Medical Technology, INC. | $50.19 | 2019-2020 | |
| Paragon 28, INC. | $37.74 | 2022-2024 | Grappler |
| Kci USA, INC. | $30.62 | 2023 | V.A.C. Dermatac, Activ.A.C., Promogran Prisma |
| Solventum Corporation | $29.93 | 2025 | Activ.A.C. |
| Organogenesis INC. | $21.09 | 2021 | |
| Janssen Biotech, INC. | $19.50 | 2024 | Stelara |
| Reapplix INC. | $16.33 | 2021 | |
| Eclipse Technology Solutions INC. | $14.14 | 2023 | |
| Integra Lifesciences Corporation | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.